



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Yamini Aiyar, Vijay Chandru, Mirai Chatterjee, Sapna Desai, Armida Fernandez, Atul Gupta, Gagandeep Kang, Tarun Khanna, Kiran Mazumdar-Shaw, Nachiket Mor, Arnab Mukherji, Poonam Muttreja, Thelma Narayan, Bhushan Patwardhan, K Sujatha Rao, Sharad Sharma, Devi Shetty, S V Subramanian, Leila E Caleb Varkey, Sandhya Venkateswaran, *Vikram Patel
 vikram_patel@hms.harvard.edu

Centre for Policy Research, New Delhi, India (YA); Indian Institute of Science, Bengaluru, India (VC); Self-Employed Women's Association, Ahmedabad, India (MC); Population Council, New Delhi, India (SD); Lokmanya Tilak Municipal Medical Hospital and College, Mumbai, India and SNEHA, Mumbai, India (AF); The Wharton School, University of Pennsylvania, Philadelphia, PA, USA (AG); Christian Medical College, Vellore, India (GK); Harvard Business School and The Lakshmi Mittal and Family South Asia Institute, Harvard University, Cambridge, MA, USA (TK); Biocon Ltd, Bengaluru, India (KM-S); The Banyan Academy of Leadership in Mental Health, Bengaluru, India (NM); Center for Public Policy, IIM Bangalore, Bengaluru, India (AM); Population Foundation of India, New Delhi, India (PM); SOCHARA, Bengaluru, India (TN); Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India (BP); Interdisciplinary AYUSH Research and Development Task Force of Ministry of AYUSH, New Delhi, India (BP); New Delhi, India (KSR); iSPIRT Foundation, Bengaluru, India (SS); Narayana Hrudayalaya Limited, Bengaluru, India (DS); Harvard Center for Population and Development Studies and Department of Social and Behavioral Sciences, Harvard T H Chan School of Public Health, Cambridge, MA, USA (SVS); Centre for Catalyzing Change, New Delhi, India (LECV); New Delhi, India (SV); Harvard Medical School and Harvard T H Chan School of Public Health, Boston, MA 02144, USA (VP); Sangath, Goa, India (VP)

- 1 Patel V, Mazumdar-Shaw K, Kang G, Das P, Khanna T. Reimagining India's health system: a Lancet Citizens' Commission. *Lancet* 2021; **397**: 1427–30.
- 2 Kuppalli K, Gala P, Cherabuddi K, et al. India's COVID-19 crisis: a call for international action. *Lancet* 2021; published online May 14. [https://doi.org/10.1016/S0140-6736\(21\)01121-1](https://doi.org/10.1016/S0140-6736(21)01121-1).
- 3 Priyamvatha P. How India's second Covid wave started, what went wrong, and what can be done: top virologist answers. *India Today*, April 28, 2021. <https://www.indiatoday.in/coronavirus-outbreak/story/india-second-covid-wave-start-went-wrong-top-virologist-answers-details-1795743-2021-04-28> (accessed May 20, 2021).
- 4 COVID19 India. Coronavirus in India: latest map and case count. 2021. <https://www.covid19india.org> (accessed May 19, 2021).
- 5 Express News Service. Triage centres in districts to fight Covid 2nd wave. *The New Indian Express*, May 17, 2021. <https://www.newindianexpress.com/states/karnataka/2021/may/17/triage-centres-in-districts-to-fight-covid-2nd-wave-2303472.html> (accessed May 19, 2021).
- 6 WHO. From governance to community resilience: Odisha's response to COVID-19. Sept 17, 2020. <https://www.who.int/india/news/feature-stories/detail/from-governance-to-community-resilience-odisha-s-response-to-covid-19> (accessed May 19, 2021).

- 7 FE Bureau. Tamil Nadu govt to bear Covid treatment expenses of public in private hospitals. *The Financial Express*, May 8, 2021. <https://www.financialexpress.com/lifestyle/health/tn-govt-to-bear-covid-treatment-expenses-of-public-in-private-hospitals/2247980/> (accessed May 19, 2021).
- 8 Finance Commission, India. <https://fincomindia.nic.in/> (accessed May 19, 2021).
- 9 WHO. COVID-19 clinical management: living guidance. 2021. <https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-clinical-2021-1> (accessed May 19, 2021).
- 10 Pulla P. Covid-19: India's slow moving treatment guidelines are misleading and harming patients. *BMJ* 2021; **372**: n278.
- 11 Wadhawan DA, Jain P, Shrivastava S, Kunal K. Rajasthan declares black fungus mucormycosis an epidemic cases rising in other states. *India Today*, May 19, 2021. <https://www.indiatoday.in/coronavirus-outbreak/story/rajasthan-declares-black-fungus-an-epidemic-cases-pile-up-in-several-states-10-points-1804470-2021-05-19> (accessed May 19, 2021).
- 12 Directorate General of Health Services, Government of India. Guideline for management of mucormycosis in COVID-19 patients. 2021. <https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf> (accessed May 20, 2021).
- 13 Ministry of AYUSH, Government of India. AYUSH guidelines. 2021. <https://www.ayush.gov.in/ayush-guidelines.html> (accessed May 20, 2021).
- 14 ET Bureau. Medical students Covid duty: on duty: final-year medical students and pre-PG doctors. *The Economic Times*, May 4, 2021. <https://economictimes.indiatimes.com/news/india/on-duty-final-yr-medical-students-pre-pg-doctors/articleshow/82378742.cms> (accessed May 19, 2021).
- 15 Lahariya C. India's vaccine policy needs an urgent reset. *Hindustan Times*, May 17, 2021. <https://www.hindustantimes.com/opinion/indias-vaccine-policy-needs-an-urgent-reset-101621261092043.html> (accessed May 19, 2021).
- 16 Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus (COVID-19) vaccinations—statistics and research. Our World in Data. 2021. <https://ourworldindata.org/covid-vaccinations> (accessed May 20, 2021).
- 17 Elyatt H. India is the home of the world's biggest producer of Covid vaccines. But it's facing a major internal shortage. *CNBC*, May 5, 2021. <https://www.cnbc.com/2021/05/05/why-covid-vaccine-producer-india-faces-major-shortage-of-doses.html> (accessed May 20, 2021).
- 18 Golechha M. COVID-19 containment in Asia's largest urban slum Dharavi-Mumbai, India: lessons for policymakers globally. *J Urban Health* 2020; **97**: 796–801.
- 19 Sharma A. Crippled by restraints, NGOs struggle to help with Covid. *Mint*, May 12, 2021. <https://www.livemint.com/news/india/why-ngos-fight-covid-with-their-hands-tied-11620834069096.html> (accessed May 19, 2021).
- 20 Morgan OW, Aguilera X, Ammon A, et al. Disease surveillance for the COVID-19 era: time for bold changes. *Lancet* 2021; published online May 14. [https://doi.org/10.1016/S0140-6736\(21\)01096-5](https://doi.org/10.1016/S0140-6736(21)01096-5).
- 21 Press Trust of India. Tamil Nadu CM Stalin extends Rs 4,000 Covid-19 assistance scheme. *Business Standard India*, May 18, 2021. https://www.business-standard.com/article/current-affairs/tamil-nadu-cm-stalin-extends-rs-4-000-covid-19-assistance-scheme-121051800804_1.html (accessed May 19, 2021).



SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties

The trade-off between different objectives is at the heart of political decision making. Public health, economic growth, democratic solidarity, and civil liberties are important factors when evaluating pandemic responses. There is mounting evidence that these objectives do not need to be in conflict in the COVID-19 response. Countries

that consistently aim for elimination—ie, maximum action to control SARS-CoV-2 and stop community transmission as quickly as possible—have generally fared better than countries that opt for mitigation—ie, action increased in a stepwise, targeted way to reduce cases so as not to overwhelm health-care systems.¹

Published Online
 April 28, 2021
[https://doi.org/10.1016/S0140-6736\(21\)00978-8](https://doi.org/10.1016/S0140-6736(21)00978-8)

For the French translation see
 Online for appendix 1
 For the Spanish translation see
 Online for appendix 2

We compared COVID-19 deaths, gross domestic product (GDP) growth, and strictness of lockdown measures during the first 12 months of the pandemic for Organisation for Economic Co-operation and Development (OECD) countries that aim for elimination or mitigation (figure).²⁻⁴ Although all indicators favour elimination, our analysis does not prove a causal connection between varying pandemic response strategies and the different outcome measures. COVID-19 deaths per 1 million population in OECD countries that opted for elimination (Australia, Iceland, Japan, New Zealand, and South Korea) have been about 25 times lower than in other OECD countries that favoured mitigation (figure). Mortality is a proxy for a country's broader disease burden. For example, decision makers should also consider the increasing evidence of long-term morbidities after SARS-CoV-2 infection.⁵

There is also increasing consensus that elimination is preferable to mitigation in relation to a country's economic performance.⁶ One study quantified the optimal basic reproduction number so that elimination is achieved at minimal economic cost.⁷ To this end, consider weekly GDP growth with respect to 2019 for the OECD countries that opted for elimination or mitigation (figure). Elimination is superior to mitigation for GDP growth on average and at almost all time periods. GDP growth returned to pre-pandemic levels in early 2021 in the five countries that opted for elimination, whereas growth is still negative for the other 32 OECD countries.

Despite its health and economic advantages, an elimination strategy has been criticised for restricting civil liberties. This claim can be challenged by analysing

the stringency index developed by researchers at the University of Oxford.² This index measures the strictness of lockdown-style policies that primarily restrict people's behaviour by combining eight indicators of containment and closure policies, eight indicators of health system policies, and one indicator of public information campaigns.² Among OECD countries, liberties were most severely impacted in those that chose mitigation, whereas swift lockdown measures—in line with elimination—were less strict and of shorter duration (figure). Importantly, elimination has been framed as a civic solidarity approach that will restore civil liberties the soonest; this focus on common purpose is frequently neglected in the political debate.

Evidence suggests that countries that opt for rapid action to eliminate SARS-CoV-2—with the strong support of their inhabitants—also better protect their economies and minimise restrictions on civil liberties compared with those that strive for mitigation. Looking ahead, mass COVID-19 vaccination is key to returning to usual life, but relying solely on COVID-19 vaccines to control the pandemic is risky due to their uneven roll-out and uptake, time-limited immunity, and the emergence of new SARS-CoV-2 variants.^{8,9} History shows that vaccination alone can neither single-handedly nor rapidly control a virus and that a combination of public health measures are needed for containment. The eradication of smallpox required concerted, decades-long efforts, including vaccination; communication and public engagement; and test, trace, and isolate measures.¹⁰ Even at the end of vaccination




Figure: COVID-19 deaths, GDP growth, and strictness of lockdown measures for OECD countries choosing SARS-CoV-2 elimination versus mitigation
 OECD countries opting for elimination are Australia, Iceland, Japan, New Zealand, and South Korea. OECD countries opting for mitigation are Austria, Belgium, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Mexico, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, the UK, and the USA. Data on strictness of lockdown measures are from Oxford COVID-19 government response tracker.² Data on COVID-19 deaths are from Our World in Data.³ Data on GDP growth are from OECD Weekly Tracker of economic activity.⁴ GDP=gross domestic product. OECD=Organisation for Economic Co-operation and Development.

campaigns, such public health measures must be maintained to some extent or new waves of infections might lead to increased morbidity and mortality.¹¹ With the proliferation of new SARS-CoV-2 variants of concern, many scientists are calling for a coordinated international strategy to eliminate SARS-CoV-2.¹²⁻¹⁵ Moreover, the US Department of State declared in April, 2021, that stopping COVID-19 is the Biden-Harris administration's number one priority and highlighted that "this pandemic won't end at home until it ends worldwide".¹⁶

National action alone is insufficient and a clear global plan to exit the pandemic is necessary. Countries that opt to live with the virus will likely pose a threat to other countries, notably those that have less access to COVID-19 vaccines. The uncertainty of lockdown timing, duration, and severity will stifle economic growth as businesses withhold investments and consumer confidence deteriorates. Global trade and travel will continue to be affected. Political indecisiveness and partisan policy decisions reduce trust in government. This does not bode well in those countries that have seen a retraction of democracy.¹⁷ Meanwhile, countries opting for elimination are likely to return to near normal: they can restart their economies, allow travel between green zones,¹⁸ and support other countries in their vaccination campaigns and beyond. The consequences of varying government COVID-19 responses will be long-lasting and extend beyond the end of the pandemic. Early economic and political gains made by countries aiming to eliminate SARS-CoV-2 will probably pay off in the long run.

IK is a member of the Global Preparedness Monitoring Board. JVL is a member of the *Lancet* COVID-19 Commission Public Health Taskforce. DS is a member of the Scottish COVID-19 Advisory Group and the UK Cabinet Office COVID-19 Advisory Group. SV is a member of Team Halo (London School of Hygiene & Tropical Medicine, the UN, and Gavi, the Vaccine Alliance). All other authors declare no competing interests.

Miquel Oliu-Barton, *Bary S R Pradelski, Philippe Aghion, Patrick Artus, Ilona Kickbusch, Jeffrey V Lazarus, Devi Sridhar, Samantha Vanderslott
bary.pradelski@cnrs.fr

Université Paris Dauphine-PSL, Paris, France (MO-B); Esade Centre for Economic Policy, Barcelona, Spain (MO-B); French National Centre of Scientific Research (CNRS), CS 40700, 38058 Grenoble cedex 9, France (BSRP); Oxford-Man Institute of Quantitative Finance, University of Oxford, Oxford, UK

(BSRP); Collège de France, Paris, France (PAG); London School of Economics and Political Science, London, UK (PAG); INSEAD, Fontainebleau, France (PAG); Natixis, Paris, France (PAR); Paris School of Economics, Paris, France (PAR); Global Health Centre, Graduate Institute of International and Development Studies, Geneva, Switzerland (IK); Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain (JVL); Global Health Governance Programme, Usher Institute of Population Health Sciences and Informatics and College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK (DS); Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK (SV)

- 1 Baker MG, Wilson N, Blakely T. Elimination could be the optimal response strategy for Covid-19 and other emerging pandemic diseases. *BMJ* 2020; **371**: m4907.
- 2 Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). *Nat Hum Behav* 2021; **5**: 529-38.
- 3 Roser M, Ritchie H, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). Our World in Data. <https://ourworldindata.org/coronavirus> (accessed April 21, 2021).
- 4 Woloszko N. Tracking activity in real time with Google Trends. OECD Economics Department Working Papers 2020, no 1634. Paris: OECD, 2020.
- 5 Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry* 2021; published April 6. [https://doi.org/10.1016/S2215-0366\(21\)00084-5](https://doi.org/10.1016/S2215-0366(21)00084-5).
- 6 Chetty R, Friedman JN, Hendren N, et al. The economic impacts of COVID-19: evidence from a new public database built using private sector data. Working paper no 27431. Cambridge, MA: National Bureau of Economic Research, 2020.
- 7 Dorn F, Khailaie S, Stoeckli M, et al. The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies. *medRxiv* 2020; published online Aug 16. <https://doi.org/10.1101/2020.08.14.20175224> (preprint).
- 8 Aschwanden C. Five reasons why COVID herd immunity is probably impossible. *Nature* 2021; **591**: 520-22.
- 9 Freeman D, Loe B, Chadwick A, et al. COVID-19 vaccine hesitancy in the UK: The Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (Oceans) II. *Psychol Med* 2020; published online Dec 11. <https://doi.org/10.1017/S0033291720005188>.
- 10 Bhattacharya S. Reflections on the eradication of smallpox. *Lancet* 2010; **375**: 1602-03.
- 11 Moore S, Hill EM, Tildesley MJ, et al. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. *Lancet Infect Dis* 2021; published online March 18. [https://doi.org/10.1016/S1473-3099\(21\)00143-2](https://doi.org/10.1016/S1473-3099(21)00143-2).
- 12 Priesemann V, Brinkmann MM, Ciesek S, et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. *Lancet* 2021; **397**: 92-93.
- 13 Priesemann V, Balling R, Brinkman MM, et al. An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* 2021; **397**: 469-70.
- 14 Oliu-Barton M, Pradelski B, Wolff GB, et al. Aiming for zero COVID-19: Europe needs to take action. 2021. <http://www.covid-greenzone.com> (accessed April 26, 2021).
- 15 Fontanet A, Autran B, Lina B, et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet* 2021; **397**: 952-54.
- 16 Blinken AJ. Secretary Antony J. Blinken remarks to the press on the COVID response. US Department of State. April 5, 2021. <https://www.state.gov/secretary-antony-j-blinken-remarks-to-the-press-on-the-covid-response/> (accessed April 21, 2021).
- 17 Bollyky TJ, Kickbusch I. Preparing democracies for pandemics. *BMJ* 2020; **371**: m4088.
- 18 Pradelski B, Oliu-Barton M. Green bridges: reconnecting Europe to avoid economic disaster. In: Bénassy-Quéré A, Weder di Mauro B, eds. Europe in the time of Covid-19. London: CEPR Press, 2020: 83-87.